TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22735040
Drug: Medication version
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication version of smoking cessation
Study: 22735040
Drug: Overall support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall support for all smoking cessation treatments
Study: 20448287
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg weekly subcutaneous etanercept added to previous DMARD treatment
Study: 20448287
Drug: Previous DMARD
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous DMARD therapy
Study: 8936753
Drug: Small group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small group treatment (3-4 patients)
Study: 8936753
Drug: Large group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large group treatment (7-8 patients)
Study: 31472003
Drug: Intact parathyroid
Normalized name: Intact parathyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact parathyroid hormone (iPTH)
Study: 27377073
Drug: Short-cycle therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-cycle therapy (SCT) (5 days on, 2 days off ART)
Study: 27377073
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy (CT) (daily ART)
Study: 15249584
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and Radiation Therapy (chemoRT)
Study: 15249584
Drug: Chemotherapy (fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (fluorouracil and levamisole)
Study: 11228276
Drug: Reviparin twice
Normalized name: reviparin
DrugBank: Reviparin (DB09259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reviparin twice daily
Study: 11228276
Drug: Reviparin once
Normalized name: reviparin
DrugBank: Reviparin (DB09259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reviparin once daily
Study: 20107201
Drug: Cyclosporine (gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (gelatin capsule microemulsion formulation)
Study: 20107201
Drug: NR1I2 genotype
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NR1I2 genotype (g.‐25385C‐g.‐24381A‐g.‐205_‐200GAGAAG‐g.7635G‐g.8055C haplotype)
Study: 17127551
Drug: Methylphenidate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate treatment for ADHD and cocaine dependence
Study: 12768117
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline dextran (HSD) (250 mL)
Study: 10705267
Drug: EH 200
Normalized name: EH-301 COMPONENT PTEROSTILBENE
DrugBank: Pterostilbene (DB17939)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EH 200 group (62 patients) using EH 200 microg/dose inhaler (1 inhalation q.i.d.)
Study: 10705267
Drug: DH group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: DH group (61 patients) using DH 200 microg/dose inhaler (1 inhalation q.i.d.)
Study: 9349931
Drug: 15-min i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-min i.v. infusion of 1 mg draflazine
Study: 30672215
Drug: Yinqi Guiyuan
Normalized name: Guiyujin (Curcuma Longa)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yinqi Guiyuan needles therapy combined with moxibustion at Yongquan (KI 1)
Study: 27270872
Drug: Curcumin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (500 mg/day equivalent to 70 mg curcumin)
Study: 22014381
Drug: Immediate Zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Immediate Zoledronic Acid (ZOL) treatment (4 mg every 6 months)
Study: 17206439
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose ingestion (75 g) without exercise
Study: 14979604
Drug: Adicanil (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adicanil (test formulation)
Study: 14979604
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available preparation (reference formulation)
Study: 12621741
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times a day administration of carbapenems (0.5 g x 3)
Study: 12621741
Drug: Twice a
Normalized name: Pataday Twice A Day Relief
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice a day administration of carbapenems (0.75 g x 2)
Study: 9818297
Drug: Amitriptyline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (25 mg tablet) with food
Study: 9818297
Drug: Amitriptyline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (25 mg tablet) fasting
Study: 25836004
Drug: Translation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Translation treatment
Study: 25836004
Drug: Controlled tipping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled tipping treatment
Study: 19174617
Drug: Haloperidol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (10 microg/kg) plus ondansetron (0.1 mg/kg)
Study: 20935397
Drug: Oral montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral montelukast (10 mg/day)
Study: 10522838
Drug: Repaglinide (0.25-4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (0.25-4.0 mg preprandially)
Study: 10522838
Drug: Repaglinide (0.5-4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (0.5-4.0 mg preprandially)
Study: 7367848
Drug: Specific hyposensitization
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific hyposensitization treatment with semi-depot extracts
Study: 29089038
Drug: N-acetylcysteine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (1200 mg) and ascorbic acid (2 g) intravenously, administered 2 hours before, and at 10 and 18 hours after contrast infusion
Study: 25582984
Drug: Low-dose combination
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combination oral contraceptive (COC)
Study: 23350584
Drug: Positive estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive estrogen receptor (ER) status
Study: 21314437
Drug: Alcaftadine ophthalmic
Normalized name: alcaftadine ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcaftadine ophthalmic solution 0.25%
Study: 21314437
Drug: Alcaftadine ophthalmic
Normalized name: alcaftadine ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcaftadine ophthalmic solution (various concentrations 0.05%-0.5%)
Study: 19223168
Drug: Pre-loading with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-loading with 500 mL of 6% hetastarch intravenously
Study: 19223168
Drug: Co-loading with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-loading with 500 mL of 6% hetastarch intravenously
Study: 17958625
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin
Study: 17415637
Drug: Oral omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral omeprazole without erythromycin
Study: 9699197
Drug: Androgen gel
Normalized name: testosterone Topical Gel [Androgel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen gel (group A)
Study: 9699197
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (group P)
Study: 8076921
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (less than one hundredth of the recommended dose of porcine calcitonin)
Study: 9468008
Drug: Chlorthalidone 25
Normalized name: chlorthalidone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 25 mg/day
Study: 2676651
Drug: Chlorthalidone 25
Normalized name: chlorthalidone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 25 mg/day + slow-release metoprolol 200 mg/day
Study: 31187552
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy (pelvic floor muscle exercises, bladder training, fluid and constipation management)
Study: 25797356
Drug: CPT‐11/CDDP (CPT‐11,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT‐11/CDDP (CPT‐11, 60 mg/m²; CDDP, 30 mg/m², q2w)
Study: 25797356
Drug: CPT‐11 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT‐11 (150 mg/m², q2w)
Study: 23590571
Drug: L-selenomethionine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-selenomethionine (200 μg daily)
Study: 16756046
Drug: Counseling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling and clinical pathway for treatment of hypoglycemia
Study: 16756046
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment for hypoglycemia
Study: 9427777
Drug: D-galactose treatment
Normalized name: D(+)-Galactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-galactose treatment
Study: 8302686
Drug: Piperacillin 4
Normalized name: piperacillin 4000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin 4 g/70 kg
Study: 8302686
Drug: Mezlocillin 5
Normalized name: Mezlocilline
DrugBank: Mezlocillin (DB00948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mezlocillin 5 g/70 kg
Study: 24942277
Drug: UFT/LV (UFT:
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT/LV (UFT: 300‐600 mg/day and LV: 75 mg/day on days 1‐28 every 35 days; five courses)
Study: 20804245
Drug: Telephone-administered cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered cognitive-behavioral therapy
Study: 18723437
Drug: Erythromycin 250
Normalized name: erythromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 250 mg twice daily
Study: 12830992
Drug: Valsartan (angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (angiotensin II antagonist)
Study: 31418989
Drug: yohimbine 54
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: yohimbine 54 mg + hydrocortisone 10 mg
Study: 27451294
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L of polyethylene glycol (PEG)
Study: 21679977
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy for prostate cancer
Study: 18507878
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (15 mg RRR-alpha-tocopherol/d)
Study: 9407254
Drug: 6% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% glucose and fructose solution at a rate of approximately 60 g/hr
Study: 9407254
Drug: Placebo (artificially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (artificially flavored solution)
Study: 8218764
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (MCP) 10 mg, three daily doses, vo
Study: 8218764
Drug: Cinitapride (CTP)
Normalized name: cinitapride
DrugBank: Cinitapride (DB08810)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinitapride (CTP) 1 mg, three daily doses, vo
Study: 31927311
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of DBS
Study: 8396101
Drug: Co-amoxiclav (13.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav (13.3 mg/kg tid for ten days)
Study: 2939870
Drug: Prazosin 13.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin 13.8 mg twice daily
Study: 31675478
Drug: H2-water (290
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-water (290 mL)
Study: 25864681
Drug: No bonding
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bonding agent used
Study: 11207173
Drug: Hypo-osmolar ORS
Normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypo-osmolar ORS (224 mmol/l)
Study: 10453599
Drug: Massage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage treatment for recurrent respiratory tract infection; details on dosage and duration not specified.
Study: 10453599
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (susceptible and healthy children); details on treatment not specified.
Study: 29635505
Drug: Intact whey
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact whey protein (15 g)
Study: 29635505
Drug: Hydrolyzed whey
Normalized name: amino acids/hydrolyzed collagen/hydrolyzed whey 15 gram-100 kcal/30 mL ORAL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrolyzed whey protein (15 g)
Study: 27569684
Drug: Both insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both insulin and saline infusion groups
Study: 26586317
Drug: Chiropractic spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic spinal manipulative therapy (CSMT)
Study: 26432128
Drug: Topical steroid-antibiotic
Normalized name: Betadine Antibiotic Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid-antibiotic alone
Study: 18091666
Drug: Guided‐tissue regeneration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided‐tissue regeneration therapy (GTR) with scaling and root planing (SRP) and application of a bioresorbable membrane
Study: 10690141
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg i.v.
Study: 9500689
Drug: ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ursodeoxycholic acid (UDCA) 23-25 mg/kg/d
Study: 2186630
Drug: ancrod 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ancrod 0.5 mu/kg in normal saline administered as a constant-rate intravenous infusion over 6 hours
Study: 31968622
Drug: Brilliant Blue
Normalized name: Brilliant blue G
DrugBank: Brilliant blue G (DB15594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brilliant Blue G (BBG)
Study: 25280823
Drug: Enhanced Treatment
Normalized name: Thera-M Enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Treatment as Usual (E-TAU)
Study: 26063508
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 2.4 mg once every 2 months + 10 μg daily for residents, 3 mg once every 2 months for carers
Study: 23860103
Drug: Active electrical
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active electrical stimulation therapy
Study: 20451663
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol 400 mg induction at weeks 0, 2, and 4; maintenance therapy randomized to every 2 weeks or every 4 weeks.
Study: 20451663
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol 400 mg every 4 weeks maintenance therapy.
Study: 20451663
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol 400 mg every 2 weeks maintenance therapy.
Study: 20451663
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with certolizumab pegol.
Study: 20451663
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with certolizumab pegol.
Study: 16868453
Drug: fluvastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluvastatin 80 mg/day
Study: 24193155
Drug: Infliximab 10
Normalized name: infliximab 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab 10 mg/kg
Study: 23952962
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral local antifungal agents alone: gargle 2% sodium bicarbonate solution for 30 s, wait 10 min and then apply 2% nystatin paste)
Study: 17397435
Drug: Oral desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral desmopressin (ddAVP)
Study: 10836283
Drug: Venlafaxine 75
Normalized name: venlafaxine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 75 mg/day (days 1-4), 150 mg/day (days 5-10), 225 mg/day (days 11-42)
Study: 10836283
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/day (days 1-4), 40 mg/day (days 5-10), 60 mg/day (days 11-42)
Study: 9096088
Drug: Technetium-99m labelled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technetium-99m labelled monoclonal antibody (MAb) 170H.82 at protein doses of 1, 2 and 4 mg
Study: 9096088
Drug: Technetium-99m labelled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technetium-99m labelled monoclonal antibody (MAb) 170H.82 at 2 mg dose
Study: 2938984
Drug: Nafarelin acetate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin acetate, D‐Nal(2)6‐GnRH, administered intranasally in a daily dose of 125 micrograms to 25 women.
Study: 2938984
Drug: Nafarelin acetate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin acetate, D‐Nal(2)6‐GnRH, administered intranasally in a daily dose of 250 micrograms to 22 women.
Study: 2938984
Drug: Nafarelin acetate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin acetate, D‐Nal(2)6‐GnRH, both doses (125 and 250 micrograms).
Study: 25031187
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group therapy (GCBT)
Study: 17565914
Drug: Ropivacaine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine administered pre‐incisionally and intraperitoneally (Group 1, n=14)
Study: 1960557
Drug: Doxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m2
Study: 7850540
Drug: Doxorubicin 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 90 mg/m2
Study: 7850540
Drug: Doxorubicin 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 120 mg/m2
Study: 27807281
Drug: Intra-arterial treatment
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial treatment in patients on prior antiplatelet treatment
Study: 27807281
Drug: Intra-arterial treatment
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial treatment in patients not on prior antiplatelet treatment
Study: 27807281
Drug: Successful reperfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful reperfusion in patients not on prior antiplatelet treatment
Study: 27807281
Drug: Symptomatic intracranial
Normalized name: ALCOHOL 80 mL in 100 mL INTRACRANIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic intracranial hemorrhage in patients on antiplatelet treatment
Study: 27807281
Drug: Symptomatic intracranial
Normalized name: ALCOHOL 80 mL in 100 mL INTRACRANIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic intracranial hemorrhage in patients without antiplatelet treatment
Study: 26194461
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus NP-delivered symptom management intervention (proactive telephone calls during the week after each of the first 2 chemotherapy visits)
Study: 10859288
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg ASA daily
Study: 10859288
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg ASA + 75 mg clopidogrel daily
Study: 12772581
Drug: 0.5% chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% chitosan mouthrinse for 14 days, rinsing with 20 ml twice daily for 30 seconds
Study: 10713862
Drug: Imipenem/cilastatin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin (1,000 mg every 12 h)
Study: 24521647
Drug: Meropenem (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (500 mg every 8 h)
Study: 25466953
Drug: Tomato juice
Normalized name: TOMATO JUICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato juice (330 ml/d) for 20 days
Study: 19339779
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of galantamine and memantine
Study: 12199273
Drug: DHEA replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA replacement therapy
Study: 2088195
Drug: Ciprofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (200 mg) + Metronidazole (500 mg)
Study: 1089875
Drug: Chenodeoxycholic acid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid, 750 mg per day
Study: 1089875
Drug: Phenobarbital, 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital, 180 mg per day
Study: 1089875
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of chenodeoxycholic acid and phenobarbital
Study: 31935028
Drug: Osocimab 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osocimab 0.3 mg/kg postoperative (n=107)
Study: 31935028
Drug: Osocimab 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osocimab 0.6 mg/kg postoperative (n=65)
Study: 31935028
Drug: Osocimab 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osocimab 1.2 mg/kg postoperative (n=108)
Study: 31935028
Drug: Osocimab 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osocimab 1.8 mg/kg postoperative (n=106)
Study: 31935028
Drug: Osocimab 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osocimab 0.3 mg/kg preoperative (n=109)
Study: 31935028
Drug: Osocimab 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osocimab 1.8 mg/kg postoperative
Study: 31935028
Drug: Osocimab 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osocimab 1.8 mg/kg preoperative
Study: 29407718
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy (CBIT, Comprehensive Behavioral Intervention for Tics)